Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
30 hedge funds and large institutions have $88.9M invested in Fusion Pharmaceuticals Inc. Common Shares in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
26% more capital invested
Capital invested by funds: $70.6M → $88.9M (+$18.3M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
12% less funds holding
Funds holding: 34 → 30 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
+$132K |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$124K |
| 3 |
Morgan Stanley
New York
|
+$77.8K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$883K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$152K |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$146K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$52K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$44K |
FUSN Hedge Fund Activity: Q4 2022 in Review
30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2022, worth a combined $88.9M — up 26% from $70.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FUSN and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Leonteq Securities AG, opening a new position worth an estimated $132K. The largest seller was Fidelity Investments, cutting an estimated $883K.
- 30 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2022, down from 34 in Q3 2022.
- Funds reported $88.9M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2022, up 26% quarter-over-quarter.
- 3 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2022 was Leonteq Securities AG, an estimated $132K added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2022 was Fidelity Investments, an estimated $883K sold.
Based on aggregated 13F filings for Q4 2022.